Enthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia. Recent changes have reignited interest in the region, with important implications for pharma executives.
Fuente: Mckensey
